Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Aloisine B
Cat. No.:
0225LY-1271
Appearance:
Solid
Purity:
≥95%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Aloisine B serves as an antiviral compound used in the study of Parkinson’s, HIV, diabetes, and Alzheimer’s through the inhibition of glycogen synthase kinase and cyclin-dependent kinase.
Synonym:
AloisineB; 496864-14-3; 6-(4-chlorophenyl)-7-propan-2-yl-5H-pyrrolo[2,3-b]pyrazine; 6-phenyl[5H]pyrrolo[2,3-b]pyrazine (aloisine) 37; 6-(4-chlorophenyl)-7-(propan-2-yl)-5H-pyrrolo[2,3-b]pyrazine; 6-(4-chlorophenyl)-7-isopropyl-5H-pyrrolo[2,3-b]pyrazine
CAS No.:
496864-14-3
Compound CID:
6538793
Formula:
C15H14ClN3
Formula Weight:
271.74
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Aloisine B can be used in kinase research to investigate the inhibition of CDK and GSK-3 pathways in various disease models.
Library Information
Target:
GSK-3; CDK
Receptor:
GSK-3; CDK
Pathways:
Wnt/β-Catenin signaling; Cell cycle; Transcription regulation; Stem cell regulation
Plate Number:
AOCL-17
Plate Location:
c8
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 184 mM
